# Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

> **NCT00729950** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 92 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** MDX-010

## Key facts

- **NCT ID:** NCT00729950
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2005-10
- **Final completion:** 2007-06
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2010-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729950, "Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00729950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*